Compare USNA & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | USNA | PCRX |
|---|---|---|
| Founded | 1992 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 317.0M | 1.0B |
| IPO Year | 1996 | 2010 |
| Metric | USNA | PCRX |
|---|---|---|
| Price | $17.21 | $23.27 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $37.60 |
| AVG Volume (30 Days) | 136.6K | ★ 754.0K |
| Earning Date | 05-18-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 107.44 |
| EPS | ★ 0.67 | 0.16 |
| Revenue | ★ $1,060,902,000.00 | $541,533,000.00 |
| Revenue This Year | $3.89 | $9.77 |
| Revenue Next Year | $6.22 | $9.71 |
| P/E Ratio | ★ $25.88 | $145.38 |
| Revenue Growth | N/A | ★ 26.04 |
| 52 Week Low | $16.80 | $18.80 |
| 52 Week High | $38.32 | $27.99 |
| Indicator | USNA | PCRX |
|---|---|---|
| Relative Strength Index (RSI) | 29.52 | 55.05 |
| Support Level | N/A | $23.10 |
| Resistance Level | $21.35 | $23.82 |
| Average True Range (ATR) | 0.70 | 1.06 |
| MACD | -0.32 | 0.08 |
| Stochastic Oscillator | 8.60 | 77.96 |
Usana Health Sciences Inc is a direct selling and direct-to-consumer nutrition, personal health and wellness company. It developed and manufactured science-based nutritional, personal care and skincare products with a focus on promoting long-term health and wellness. The company has two reportable segments: direct selling and Hiya direct-to-consumer. The direct selling segment develops and manufactures high quality, science-based nutritional, personal care and skincare products with a focus on promoting long-term health and wellness in various geographic markets that are distributed through the direct selling channel. The Hiya direct-to-consumer segment is a provider of children's health and wellness products in the U.S. Key revenue is generated from Direct selling segment.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.